Literature DB >> 18559532

Human T-cell leukemia virus I tax protein sensitizes p53-mutant cells to DNA damage.

Valia T Mihaylova1, Allison M Green, Moshe Khurgel, Oliver J Semmes, Gary M Kupfer.   

Abstract

Mutations in p53 are a common cause of resistance of cancers to standard chemotherapy and, thus, treatment failure. Reports have shown that Tax, a human T-cell leukemia virus type I encoded protein that has been associated with genomic instability and perturbation of transcription and cell cycle, sensitizes HeLa cells to UV treatment. The extent to which Tax can sensitize cells and the mechanism by which it exerts its effect are unknown. In this study, we show that Tax sensitizes p53-mutant cells to a broad range of DNA-damaging agents, including mitomycin C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing radiation, a double-strand break agent, or vinblastine, a tubulin poison. Tax caused hypersensitivity in all p53-deleted cell lines and several, but not all, mutant-expressed p53-containing cell lines, while unexpectedly being protective in p53 wild-type (wt) cells. The effect observed in p53-deleted lines could be reversed for this by transfection of wt p53. We also show that Tax activates a p53-independent proapoptotic program through decreased expression of the retinoblastoma protein and subsequent increased E2F1 expression. The expression of several proapoptotic proteins was also induced by Tax, including Puma and Noxa, culminating in a substantial increase in Bax dimerization. Our results show that Tax can sensitize p53-mutant cells to DNA damage while protecting p53 wt cells, a side benefit that might result in reduced toxicity in normal cells. Such studies hold the promise of a novel adjunctive therapy that could make cancer chemotherapy more effective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559532      PMCID: PMC5939382          DOI: 10.1158/0008-5472.CAN-07-5070

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Direct coupling of the cell cycle and cell death machinery by E2F.

Authors:  Zaher Nahle; Julia Polakoff; Ramana V Davuluri; Mila E McCurrach; Matthew D Jacobson; Masashi Narita; Michael Q Zhang; Yuri Lazebnik; Dafna Bar-Sagi; Scott W Lowe
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

Review 2.  The E2F transcription factors: key regulators of cell proliferation.

Authors:  H Müller; K Helin
Journal:  Biochim Biophys Acta       Date:  2000-02-14

3.  Chk2 molecular interaction map and rationale for Chk2 inhibitors.

Authors:  Yves Pommier; John N Weinstein; Mirit I Aladjem; Kurt W Kohn
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

4.  Apaf1 is required for mitochondrial pathways of apoptosis and brain development.

Authors:  H Yoshida; Y Y Kong; R Yoshida; A J Elia; A Hakem; R Hakem; J M Penninger; T W Mak
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

Review 5.  p53 and response to chemotherapy and radiotherapy.

Authors:  H E Ruley
Journal:  Important Adv Oncol       Date:  1996

6.  Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells.

Authors:  Pedro J Real; Cristina Sanz; Olga Gutierrez; Carlos Pipaon; Ana M Zubiaga; Jose L Fernandez-Luna
Journal:  FEBS Lett       Date:  2006-10-02       Impact factor: 4.124

7.  Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.

Authors:  F Moroni; E Meli; F Peruginelli; A Chiarugi; A Cozzi; R Picca; P Romagnoli; R Pellicciari; D E Pellegrini-Giampietro
Journal:  Cell Death Differ       Date:  2001-09       Impact factor: 15.828

8.  The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation.

Authors:  Kylene Kehn; Cynthia de la Fuente; Katharine Strouss; Reem Berro; Hua Jiang; John Brady; Renaud Mahieux; Anne Pumfery; Maria Elena Bottazzi; Fatah Kashanchi
Journal:  Oncogene       Date:  2005-01-20       Impact factor: 9.867

9.  Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators.

Authors:  R Mahieux; C A Pise-Masison; C Nicot; P Green; W W Hall; J N Brady
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

10.  Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2.

Authors:  Iqbal H Chowdhury; Arash Farhadi; Xiao-Fan Wang; Merlin L Robb; Deborah L Birx; Jerome H Kim
Journal:  Int J Cancer       Date:  2003-11-20       Impact factor: 7.396

View more
  2 in total

Review 1.  Move or die: the fate of the Tax oncoprotein of HTLV-1.

Authors:  Julie Lodewick; Isabelle Lamsoul; Françoise Bex
Journal:  Viruses       Date:  2011-06-15       Impact factor: 5.048

Review 2.  Modulation of DNA damage and repair pathways by human tumour viruses.

Authors:  Robert Hollingworth; Roger J Grand
Journal:  Viruses       Date:  2015-05-22       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.